MedTrace Logo

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

NCT07788118 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-08-26

No results posted yet for this study

Summary

This study is aimed to explored the safety and efficacy of 7×19-THEMIS CAR-T cell therapy for large B-cell lymphoma and to conduct an exploratory comparison of the 3-month objective response rate (ORR) and complete remission rate (CR rate) between the experimental cohort and the historical control cohort (NCT04833504).

Conditions

  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Transforming Follicular Lymphoma (tFL)
  • Mantle Cell Lymphoma (MCL)

Interventions

BIOLOGICAL

7×19-THEMIS CAR-T cells

IL7 and CCL19 Armed anti-CD19 CAR-T with coexpressing Themis

Sponsors & Collaborators

  • Second Affiliated Hospital, Zhejiang University, School of Medicine

    lead OTHER

Principal Investigators

  • Wenbin Qian,Professor · Second Affiliated Hospital, Zhejiang University, School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2029-09-01
Completion
2031-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07788118 on ClinicalTrials.gov